CLINICAL TRIALS PROFILE FOR ABLAVAR
✉ Email this page to a colleague
All Clinical Trials for ABLAVAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00375830 ↗ | Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases | Completed | Stanford University | Phase 2 | 2006-01-01 | This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. |
| NCT01135316 ↗ | Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR | Completed | Lantheus Medical Imaging | 2009-10-01 | Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months. | |
| NCT01165892 ↗ | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Completed | Lantheus Medical Imaging | 2011-07-01 | The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI). | |
| NCT01165892 ↗ | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Completed | Washington University School of Medicine | 2011-07-01 | The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI). | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABLAVAR
Condition Name
Clinical Trial Locations for ABLAVAR
Trials by Country
Clinical Trial Progress for ABLAVAR
Clinical Trial Phase
Clinical Trial Sponsors for ABLAVAR
Sponsor Name
